Deadline: 19-Feb-2026
The Pfizer Competitive Grant Program in Italy supports investigator-sponsored research on real-world use of abrocitinib for adult atopic dermatitis patients. Grants of up to €50,000 per project are available for studies completed within 12 months, aiming to generate clinical evidence that improves patient outcomes and informs therapeutic practice.
Overview
Pfizer is inviting applications for its Competitive Grant Program, focusing on independent, investigator-led research initiatives that address unmet medical needs. This call emphasizes real-world clinical data on the use of abrocitinib in adult patients with atopic dermatitis within Italian healthcare settings.
Who is Eligible?
-
Organisations based in Italy capable of receiving funding directly
-
Principal Investigator (PI) must be located in Italy, hold a medical or doctoral degree, and be employed by the requesting organisation
-
Collaborative projects across departments or institutions are allowed if the requesting organisation plays a central role
Research Focus
Eligible proposals should:
-
Generate real-world evidence on the effectiveness and safety of abrocitinib
-
Align with current therapeutic guidelines for atopic dermatitis
-
Address gaps in patient management in Italian clinical practice
-
Focus on outcomes that can inform clinical decision-making
Funding Details
-
Individual projects can request up to €50,000
-
Total budget for this call: €200,000
-
Maximum project duration: 12 months
-
All research must be fully investigator-led
How to Apply / How It Works
-
Identify a relevant research question aligned with real-world use of abrocitinib
-
Prepare a complete proposal including:
-
Study objectives and design
-
Methodology and data collection plan
-
Expected impact on patient outcomes
-
Compliance with regulatory requirements
-
-
Submit through the designated Pfizer submission portal
-
Ensure the PI and organisation meet all eligibility requirements
-
Collaborative proposals must clearly define roles and responsibilities
Why It Matters
-
Supports independent scientific research while maintaining study integrity
-
Provides real-world evidence to improve atopic dermatitis care in Italy
-
Helps close gaps in clinical knowledge and patient management
-
Encourages collaboration across departments and institutions
Tips for Applicants
-
Focus on practical, evidence-generating research relevant to Italian clinical practice
-
Ensure the study design complies with ethical and regulatory standards
-
Clearly demonstrate the central role of the requesting organisation in collaborative proposals
-
Prepare a realistic budget and timeline within the 12-month limit
Frequently Asked Questions (FAQ)
1. Who can apply?
Italian-based organisations with a PI holding a medical or doctoral degree, employed by the organisation.
2. Can the project involve multiple institutions?
Yes, but the requesting organisation must play a central coordinating role.
3. What is the maximum grant amount?
€50,000 per project, with a total call budget of €200,000.
4. What is the required project duration?
Projects must be completed within 12 months.
5. Does Pfizer assist with study design?
No, all funded projects must be investigator-led; Pfizer does not participate in protocol development or execution.
6. What types of data are expected?
Real-world clinical data on the effectiveness and safety of abrocitinib in adult atopic dermatitis patients.
7. Are applications limited to Italy?
Yes, both the organisation and the PI must be based in Italy.
Conclusion
The Pfizer Competitive Grant Program offers Italian researchers the opportunity to conduct independent, investigator-led studies that generate meaningful real-world evidence on abrocitinib use in atopic dermatitis. This funding supports scientific rigor, clinical relevance, and improvements in patient outcomes across Italian healthcare settings.
For more information, visit Pfizer.
